Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation

Saudi Medical Journal

Volumn 28, Issue 11, 2007, Pages 1745-1747

  Bukhari, Iqbal A ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; ETRETIN; METHOTREXATE; PSORALEN;

ADULT; ANKLE EDEMA; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; PHOTOTHERAPY; PSORIASIS VULGARIS; REBOUND; RELAPSE; SAUDI ARABIA; SYSTEMIC THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; PSORIASIS; RECURRENCE; SAUDI ARABIA;

EID: 36949032353     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157: 4986-4895.
2. Carey W, Glazer S, Gottlieb A, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dematol 2006; 54: S171-S181.
3. de Jong EM. The course of psoriasis. Clin Dermatol 1997; 15: 687-692.
4. Koo J. Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41: S25-S28.
5. hamilton TK. Clinical considerations of efaluzimab therapy in patients with psoriasis. Semin Cutan Med Surg 2005; 24: 19-27.